Bird Rock Bio Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Bird Rock Bio Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10842
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bird Rock Bio Inc (Bird Rock Bio), formerly RuiYi Inc is a clinical stage biopharmaceutical company that develops immuno-inflammatory regulators and therapeutic antiobodies. The company’s pipeline products include RYI-018, Gerilimzumab and Namacizumab. Its RYI-018 is a peripheral antagonist antibody to cannabinoid receptor 1 intended for the treatment of nonalcoholic steatohepatitis, fibrotic and metabolic diseases, and others. Bird Rock Bio’s Gerilimzumab is a novel anti IL-6 antibody indicated to treat rheumatoid arthritis, inflammatory and autoimmune diseases. The company partners with research institutes and pharmaceutical companies for its product development activities. Bird Rock Bio is headquartered in La Jolla, California, the US.

Bird Rock Bio Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bird Rock Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Bird Rock Bio Raises USD5 Million in Venture Financing 10
RuiYi Raises US$15 Million In Series B Financing 11
Partnerships 13
Bird Rock Bio Enters into agreement with GE Healthcare 13
Janssen Pharma Enters into Partnership with Bird Rock Bio 14
RuiYi Enters into Agreement with iHuman Institute to Develop Novel Antibodies 15
CMC Biologics Enters Into Co-Development Agreement With RuiYi For RYI-008 Cell Line 16
Licensing Agreements 17
Bird Rock Bio Enters into Licensing Agreement with arGEN-X for ARGX-109 17
RuiYi Enters Into Licensing Agreement With Genor BioPharma For RYI-008 19
Acquisition 20
Anaphore Acquires RuiYi, Developer Of GPCR Biologics 20
Bird Rock Bio Inc – Key Competitors 21
Bird Rock Bio Inc – Key Employees 22
Bird Rock Bio Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Clinical Trials 24
Sep 13, 2018: Bird Rock Bio completes clinical trial of Nimacimab in patients with fatty liver disease 24
Jun 05, 2017: Bird Rock Bio Completes Single Ascending Dose Human Clinical Trial for Namacizumab; Generates Safety, Tolerability, and Pharmacokinetics Data; Prepares To Initiate Study in Non-Alcoholic Fatty Liver Disease Patients 25
Jan 11, 2017: Bird Rock Bio Receives Approval to Start First in Human Clinical Trial for Namacizumab 26
Jan 03, 2017: Bird Rock Bio Receives Approval from ANVISA and CONEP to Initiate the First Phase 2 Study in Brazil of Gerilimzumab for Rheumatoid Arthritis 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Key Facts 2
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bird Rock Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bird Rock Bio Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Bird Rock Bio Raises USD5 Million in Venture Financing 10
RuiYi Raises US$15 Million In Series B Financing 11
Bird Rock Bio Enters into agreement with GE Healthcare 13
Janssen Pharma Enters into Partnership with Bird Rock Bio 14
RuiYi Enters into Agreement with iHuman Institute to Develop Novel Antibodies 15
CMC Biologics Enters Into Co-Development Agreement With RuiYi For RYI-008 Cell Line 16
Bird Rock Bio Enters into Licensing Agreement with arGEN-X for ARGX-109 17
RuiYi Enters Into Licensing Agreement With Genor BioPharma For RYI-008 19
Anaphore Acquires RuiYi, Developer Of GPCR Biologics 20
Bird Rock Bio Inc, Key Competitors 21
Bird Rock Bio Inc, Key Employees 22

List of Figures
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Bird Rock Bio Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • GlobalLogic, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' GlobalLogic, Inc. Mergers and A …
  • UNIQA Romania:企業の戦略・SWOT・財務情報
    UNIQA Romania - Strategy, SWOT and Corporate Finance Report Summary UNIQA Romania - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Pegasystems Inc. (PEGA):企業概要、財務及び戦略的SWOT分析
    Summary Pegasystems Inc. (Pegasystems) is an information technology solution provider. The company provides business process management software solutions. Its products and services include SmartBPM suite, SmartPaaS, PegaRULES, internet application composer, business process management, customer rel …
  • GSO Capital Partners LP:企業のM&A・提携動向(エネルギー分野)
    Summary GSO Capital Partners LP (GSO Capital) is a credit-focused alternative asset manager that delivers superior risk-adjusted returns and capital preservation. It provides a broad array of credit services across a range of non-investment grade disciplines such as leveraged loans, mezzanine financ …
  • Indianapolis Power & Light Company:企業概要及び戦略的SWOT分析
    Indianapolis Power & Light Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Oberoi Realty Limited:企業の戦略・SWOT・財務分析
    SummaryOberoi Realty Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key F …
  • Tepha Inc-医療機器分野:企業M&A・提携分析
    Summary Tepha Inc (Tepha) is a medical device company that develops and commercializes medical device components and finished goods. The company offers products such as absorbable monofilament suture, absorbable monofilament mesh, composite mesh and absorbable surgical film. It also provides platfor …
  • Invuity Inc (IVTY)-医療機器分野:企業M&A・提携分析
    Summary Invuity Inc (Invuity) is a medical technology company that offers visualization products for the less invasive surgical procedures. The company offers handhelds, retractors and drop-ins. Its handhelds products include saber frazier and saber yankauer. Invuity offers retractors such as breite …
  • Seikagaku Corp (4548):企業の財務・戦略的SWOT分析
    Summary Seikagaku Corp (Seikagaku) is a manufacturer and supplier of pharmaceuticals and medical devices. The company offers products such as pharmaceuticals and medical devices, bulk products, endotoxin-detecting reagents and oral care products. It manufactures and markets pharmaceutical products c …
  • Endocyte, Inc. (ECYT):企業概要、財務及び戦略的SWOT分析
    Summary Endocyte, Inc. (Endocyte) is a biopharmaceutical company. The company develops and markets therapies for the treatment of cancer and other inflammatory diseases. Its pipeline products include Vynfinit is used in the treatment of non-small cell lung cancer and carboplatin/paclitaxel combinati …
  • INES Corporation (9742):企業概要、財務及び戦略的SWOT分析
    Summary INES Corporation (INES) is an information technology company. The company provides a range of integrated software services to various customers. Its services include data-processing and communication network services, software development, system integration services and other system-related …
  • China Life Insurance Company Limited:企業概要およびSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "China Life Insurance Company Limited" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetr …
  • Viacom, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Viacom, Inc. Mergers and Acquis …
  • Gold Fields Ltd:戦略・SWOT・企業財務分析
    Gold Fields Ltd - Strategy, SWOT and Corporate Finance Report Summary Gold Fields Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Evrofarma S.A.:企業の戦略・SWOT・財務分析
    SummaryEvrofarma S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings …
  • Denbury Resources Inc. (DNR):企業のM&A・提携動向(石油・ガス分野)
    Summary Denbury Resources Inc. (Denbury) is an independent upstream oil and gas company. The company explores for develops and produces oil and natural from its assets in Gulf coast and Rocky mountain region in the US. Denbury owns the largest carbon dioxide (CO2) reserves in the East of the Mississ …
  • Informa plc:企業の戦略・SWOT・財務情報
    Informa plc - Strategy, SWOT and Corporate Finance Report Summary Informa plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Athenex Inc (ATNX):製薬・医療:M&Aディール及び事業提携情報
    Summary Athenex Inc (Athenex), formerly Kinex Pharmaceuticals LLC, is a biopharmaceutical company focused on the discovery, development and commercialization novel medicines and cell therapies for the treatment of cancers. The company’s orascovery products candidates include oral formulations of pac …
  • UCO Bank Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' UCO Bank Limited Mergers and Ac …
  • Fitbit Inc.:企業の戦略・SWOT・財務情報
    Fitbit Inc. - Strategy, SWOT and Corporate Finance Report Summary Fitbit Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆